Mezigdomide
Mezigdomide is the most potent oral cereblon modulator, producing responses in about 40% of triple-class-refractory myeloma with dexamethasone alone.
CC-92480-MM-001: ORR 41% (MeziDex) in heavily pretreated disease including 30% with extramedullary disease. SUCCESSOR-1 (Mezi-Vd vs Pom-Vd) and SUCCESSOR-2 (Mezi-Kd vs Kd) phase 3 trials ongoing.
Compare all products across the US, EU, UK, Japan, China and Australia →
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Mezigdomide" OR ABSTRACT:"Mezigdomide" OR TITLE:"CC-92480" OR ABSTRACT:"CC-92480") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mezigdomide, not a curated reading list.